Mastery Pathway: Pituitary Course
Mastery Pathway: Pituitary Course
Welcome to the ENDO 2020 Clinical Mastery Pathway for Pituitary Disease!
The Pituitary Disease Mastery Pathway will:
- Provide clinicians with a themed, topic-based learning opportunity within the ENDO 2020 meeting.
- Highlight a curated selection of sessions and activities on a topic area with guidance from a leading
subject-matter expert who provides specialized, dedicated teaching.
- Provide knowledge assessment and a certificate of mastery to build participant confidence for relevant board
exams or to update the participant on am area of clinical practice.
- Create a dedicated ‘community of learning’ around a shared topic of interest within ENDO and provide opportunities for shared professional development and networking.
Who should sign up for a Mastery Pathway?
You should consider a Mastery Pathway if you would like to pursue a curated ‘meeting within a meeting’ with more focused and defined learning objectives compared to the entire ENDO 2020 conference. Mastery Pathways are designed for both clinical trainees or fellows attending ENDO for the first time and more experienced clinicians looking for a refresher. Mastery Pathways are also designed for those seeking to join a more intimate learning network.
Upon completion of the Pituitary Disease Mastery Pathway, participants will be able to:
- Describe the long-term management of patients treated for functioning pituitary adenomas, including potential nlasting complications, such as growth hormone, gonadotrophin, and prolactin excess.
- Outline the natural progression of both treated and untreated pituitary adenomas and identify the optimal imaging protocols.
- Describe the impact of pituitary insults, such as traumatic brain injury or irradiation, on functioning.
The Pituitary Disease Pathway is led by Mark E. Molitch, MD, who is a leading expert in the field and practicing clinician. Dr. Molitch will serve as a mentor throughout the meeting and will facilitate special pathway sessions featuring interactive discussions. Dr. Molitch graduated from the University of Pennsylvania School of Medicine in 1969. He did his housestaff training at the Hospital of the University of Pennsylvania and his Endocrine Fellowship at UCLA-Harbor General Hospital in Los Angeles. At present, he is the Martha Leland Sherwin Emeritus Professor of Endocrinology at Northwestern in the Division of Endocrinology, Metabolism and Molecular Medicine. In addition to editing eight books and journal volumes, Dr. Molitch has authored or coauthored more than 500 original papers, review articles, book chapters, case reports and other publications. In 1997, Dr. Molitch was named "Outstanding Physician Educator in the Field of Diabetes" by the American Diabetes Association. He was awarded the "Distinguished Educator Award" of The Endocrine Society for 2013. He was elected to the Council of The Endocrine Society from 2007 to 2010 and completed a three-year term as the Chair of The Endocrine Society's Clinical Endocrinology Update in 2012. He was also the President of The Pituitary Society from 2012-2013.
Dr. Mark Molitch, MD
Professor Maralyn Druce
Barts and the London School of Medicine, QMUL
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships:
Mark E. Molitch, MD: Consulting Fee; Self; Merck & Co., Pfizer, Inc., Novartis Pharmaceuticals, Janssen Research & Development Company. Grant Recipient; Self; Novartis Pharmaceuticals, Bayer, Inc., Strongbridge, Chiasma, Novo Nordisk. Advisory Board Member; Self; Jansen Pharmaceuticals, Sanofi.
Professor Maralyn Druce, MA, FRCP, PhD: Editor-in-Chief; Self; Endocrinology, Diabetes & Metabolism Case Reports. Advisory Board Member; Self; Specific Consultations, Ipsen. Chair of Public Engagement Committee; Self; Society for Endocrinology Medical Advisory Board Member; Self; AMEND Charity. Editorial Board Member; Self; Clinical Endocrinology (Oxf), Endocrine Related Cancer.
USE OF PROFESSIONAL JUDGMENT:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is not supported by educational grant(s) or other funds from any commercial supporter.
There is no credit being offered for this product.